Proactive Investors - Run By Investors For Investors

THC Global Group Ltd granted trading halt by ASX

THC Global operates under a ‘Farm to Pharma’ pharmaceutical model.
ASX through glass window
Shares in the company last traded at 42 cents before going into halt

THC Global Group Ltd (ASX:THC) has been granted a trading halt by the ASX pending the release of information regarding the grant of a manufacture licence by the Office of Drug Control.

Shares in the company will remain halted until the earlier of either, the release of relevant information, or, the commencement of trading next Tuesday 9 July 2019.

READ: THC Global has full suite of cannabis licences to advance farm-to-pharma model

THC is in a prime position to commence medicinal cannabis production to service both domestic patients and the global export market.

The company is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East.

In addition to its core Australian medicinal cannabis assets, THC has a significant Canadian presence – both in cannabis and in hydroponics equipment.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
tablets and pills
July 16 2019
Here we take a closer look at Clinigen, the specialty pharma group and AIM billionaire
scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use